Bigbear Pharmaceutical·Medication Guide

• Quizartinib Dosage Guidelines

  However, adherence to prescribed medication regimens directly impacts treatment efficacy and patient safety when using quizartinib. Patients should st···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 162

• Side Effects of Quizartinib

  Quizartinib needs to be used in combination with chemotherapy and maintained long-term. During treatment, a range of treatment-related adverse reactio···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 158

• Indications for Quizartinib:

  Quizartinib is a tyrosine kinase inhibitor (TKI) indicated for newly diagnosed adult patients with FLT3-ITD mutation-positive acute myeloid leukemia (···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 153

• How Much Does Vanflyta (Quizartinib) Cost? Full Price Breakdown by Year

  The price of quezartinib is affected by factors such as region, dosage, and purchase channel. It is not yet officially available in China, and the pri···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 154

• The European Commission has approved VANFLYTA (quizartinib), a targeted therapy

  Recently, the European Commission (EC) authorized VANFLYTA in combination with standard cytarabine and anthracycline induction therapy, followed by st···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 165

• VANFLYTA is now available in the US and Japan

  According to a press release yesterday from Daiichi Sankyo Pharmaceutical Co., Ltd., VANFLYTA (quizartinib) has been launched in the United States. Th···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 156

• Vanflyta (quizartinib) Approved by FDA for FLT3-ITD-Positive Acute Myeloid Leukemia

  Daiichi Sankyo announced on July 20 that the U.S. Food and Drug Administration (FDA) has approved Vanflyta (quizartinib) in combination with standard ···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 165

• ​The oral FLT3 inhibitor Vanflyta has been approved again in Japan for the treatment of newly diagno

  Yesterday, Daiichi Sankyo Pharmaceutical announced in a press release that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 163

• Quizartinib Receives FDA Priority Review for Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemi

  The U.S. FDA has recently accepted and granted priority review to quizartinib's New Drug Application (NDA). The NDA grant is for the treatment of ···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 161

• What other medications may affect pemigatinib?

  Certain medications should not be used together due to safety concerns. Some drugs can alter blood concentrations of other medications you are taking,···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 159

• What should I avoid while taking pemigatinib?

  Grapefruit and grapefruit products may interact with pemigatinib and increase the risk of adverse side effects. Therefore, avoid consuming grapefruit ···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 157

• What if I take too much (overdose)?

  Seek immediate emergency medical help or call the Poison Help hotline.【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 158

• What if I miss a dose of pemigatinib?

  Take your dose as soon as you remember. However, if it has been more than 4 hours since your scheduled dose, skip the missed one. Do not take a double···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 157

• Indications for Pemigatinib

  Pemigatinib demonstrates proven therapeutic activity in patients with previously treated locally advanced/metastatic cholangiocarcinoma and FGFR2 fusi···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 161

• Side Effects of Pemigatinib

  While pemigatinib exerts its therapeutic effect, it may cause different types and degrees of side effects due to individual differences in physical co···【Read More】

  Update: 2026-04-09Source: Haiou HealthViews: 152